JP2014524748A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014524748A5 JP2014524748A5 JP2014520658A JP2014520658A JP2014524748A5 JP 2014524748 A5 JP2014524748 A5 JP 2014524748A5 JP 2014520658 A JP2014520658 A JP 2014520658A JP 2014520658 A JP2014520658 A JP 2014520658A JP 2014524748 A5 JP2014524748 A5 JP 2014524748A5
- Authority
- JP
- Japan
- Prior art keywords
- binding protein
- antigen
- antigen binding
- seq
- substitution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000025171 antigen binding proteins Human genes 0.000 claims 41
- 108091000831 antigen binding proteins Proteins 0.000 claims 41
- 238000006467 substitution reaction Methods 0.000 claims 16
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 3
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000004681 Psoriasis Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 1
- 102000009109 Fc receptors Human genes 0.000 claims 1
- 108010087819 Fc receptors Proteins 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- 241000269435 Rana <genus> Species 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 238000012217 deletion Methods 0.000 claims 1
- 230000037430 deletion Effects 0.000 claims 1
- 230000001605 fetal effect Effects 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 239000002773 nucleotide Substances 0.000 claims 1
- 125000003729 nucleotide group Chemical group 0.000 claims 1
- 208000019764 polyarticular juvenile idiopathic arthritis Diseases 0.000 claims 1
- 230000006916 protein interaction Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 230000007306 turnover Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1112429.4A GB201112429D0 (en) | 2011-07-19 | 2011-07-19 | Antigen-binding proteins with increased FcRn binding |
| GB1112429.4 | 2011-07-19 | ||
| PCT/EP2012/064129 WO2013011076A2 (en) | 2011-07-19 | 2012-07-19 | Antigen-binding proteins with increased fcrn binding |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014524748A JP2014524748A (ja) | 2014-09-25 |
| JP2014524748A5 true JP2014524748A5 (enExample) | 2015-08-13 |
Family
ID=44586854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014520658A Pending JP2014524748A (ja) | 2011-07-19 | 2012-07-19 | FcRn結合の増加したTNF−α抗原結合タンパク質 |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20130243764A1 (enExample) |
| EP (2) | EP3009450A1 (enExample) |
| JP (1) | JP2014524748A (enExample) |
| KR (1) | KR20140054085A (enExample) |
| CN (1) | CN103748110A (enExample) |
| AU (1) | AU2012285786B2 (enExample) |
| BR (1) | BR112014000341A2 (enExample) |
| CA (1) | CA2841105A1 (enExample) |
| CL (1) | CL2014000134A1 (enExample) |
| CO (1) | CO6862106A2 (enExample) |
| CR (1) | CR20140029A (enExample) |
| DO (1) | DOP2014000007A (enExample) |
| EA (1) | EA201391789A1 (enExample) |
| ES (1) | ES2600854T3 (enExample) |
| GB (1) | GB201112429D0 (enExample) |
| MA (1) | MA35345B1 (enExample) |
| MX (1) | MX2014000739A (enExample) |
| PE (1) | PE20141660A1 (enExample) |
| PH (1) | PH12014500167A1 (enExample) |
| SG (1) | SG10201601154QA (enExample) |
| WO (1) | WO2013011076A2 (enExample) |
| ZA (1) | ZA201400062B (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2385745C (en) | 2001-06-08 | 2015-02-17 | Abbott Laboratories (Bermuda) Ltd. | Methods of administering anti-tnf.alpha. antibodies |
| AR083495A1 (es) | 2010-10-22 | 2013-02-27 | Esbatech Alcon Biomed Res Unit | Anticuerpos estables y solubles |
| EP2702077A2 (en) | 2011-04-27 | 2014-03-05 | AbbVie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
| JP2015509526A (ja) | 2012-03-07 | 2015-03-30 | カディラ ヘルスケア リミティド | 医薬製剤 |
| US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
| US9334319B2 (en) | 2012-04-20 | 2016-05-10 | Abbvie Inc. | Low acidic species compositions |
| US9505833B2 (en) | 2012-04-20 | 2016-11-29 | Abbvie Inc. | Human antibodies that bind human TNF-alpha and methods of preparing the same |
| WO2013158275A1 (en) * | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Cell culture methods to reduce acidic species |
| US9181572B2 (en) | 2012-04-20 | 2015-11-10 | Abbvie, Inc. | Methods to modulate lysine variant distribution |
| WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
| WO2013186230A1 (en) * | 2012-06-12 | 2013-12-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical formulation for a therapeutic antibody |
| HK1211981A1 (en) | 2012-09-02 | 2016-06-03 | Abbvie Inc. | Methods to control protein heterogeneity |
| US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
| AU2013312300A1 (en) | 2012-09-07 | 2015-04-16 | Coherus Biosciences, Inc. | Stable aqueous formulations of adalimumab |
| FR2999431B1 (fr) * | 2012-12-17 | 2016-03-18 | Lfb Biotechnologies | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
| CA2894225A1 (fr) * | 2012-12-17 | 2014-06-26 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes |
| CN105051064A (zh) * | 2013-01-24 | 2015-11-11 | 葛兰素史克知识产权开发有限公司 | 抗TNF-α抗原结合蛋白 |
| AU2013384204B2 (en) * | 2013-03-14 | 2017-03-16 | Abbvie Inc. | Low acidic species compositions and methods for producing and using the same |
| WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
| WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
| US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
| EP3021833B2 (en) * | 2013-07-19 | 2022-03-30 | Hexal Aktiengesellschaft | Methods and formulations which allow the modulation of immune responses related to the administration of a biopharmaceutical drug |
| WO2015051293A2 (en) | 2013-10-04 | 2015-04-09 | Abbvie, Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
| WO2015057910A1 (en) | 2013-10-16 | 2015-04-23 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
| US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
| US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
| US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
| US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
| EP2946766B1 (en) | 2014-05-23 | 2016-03-02 | Ares Trading S.A. | Liquid pharmaceutical composition |
| HUE029849T2 (en) * | 2014-05-23 | 2017-04-28 | Ares Trading Sa | Liquid pharmaceutical composition |
| ES2607489T3 (es) | 2014-05-23 | 2017-03-31 | Ares Trading S.A. | Composición farmacéutica líquida |
| MY192824A (en) * | 2014-09-03 | 2022-09-12 | Boehringer Ingelheim Int | Compound targeting il-23a and tnf-alpha and uses thereof |
| HUP1400510A1 (hu) * | 2014-10-28 | 2016-05-30 | Richter Gedeon Nyrt | Gyógyászati TNFalfa ellenes antitest készítmény |
| US10696735B2 (en) | 2015-01-21 | 2020-06-30 | Outlook Therapeutics, Inc. | Modulation of charge variants in a monoclonal antibody composition |
| EP3250598A1 (en) * | 2015-01-28 | 2017-12-06 | Mabxience S.A. | Pharmaceutical formulations for anti-tnf-alpha antibodies |
| WO2016189491A1 (en) * | 2015-05-28 | 2016-12-01 | Glaxosmithkline Intellectual Property Development Limited | Novel formulation |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| GB201522394D0 (en) | 2015-12-18 | 2016-02-03 | Ucb Biopharma Sprl | Antibodies |
| JP6954842B2 (ja) * | 2015-12-25 | 2021-10-27 | 中外製薬株式会社 | 増強された活性を有する抗体及びその改変方法 |
| EP3411401A1 (en) | 2016-02-03 | 2018-12-12 | Oncobiologics, Inc. | Buffer formulations for enhanced antibody stability |
| CR20180445A (es) | 2016-03-14 | 2019-02-08 | Univ Oslo | Inmunoglobulinas diseñadas por ingeniería genética con unión alterada al fcrn |
| US11071782B2 (en) | 2016-04-20 | 2021-07-27 | Coherus Biosciences, Inc. | Method of filling a container with no headspace |
| AU2017255077B2 (en) | 2016-04-28 | 2024-05-16 | Chugai Seiyaku Kabushiki Kaisha | Antibody-containing preparation |
| AU2017303205B2 (en) | 2016-07-29 | 2024-08-01 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibody exhibiting increased alternative FVIII-cofactor-function activity |
| KR20250036943A (ko) | 2016-08-02 | 2025-03-14 | 비스테라, 인크. | 조작된 폴리펩티드 및 그의 용도 |
| TWI778985B (zh) * | 2016-10-20 | 2022-10-01 | 法商賽諾菲公司 | 抗chikv抗體及其用途 |
| CN120392659A (zh) | 2017-01-11 | 2025-08-01 | 赛特瑞恩股份有限公司 | 稳定的液体调配物 |
| WO2018129713A1 (zh) * | 2017-01-13 | 2018-07-19 | 杭州翰思生物医药有限公司 | 提高IgG类抗体对FcRn的结合亲和力并延长其血清半衰期的方法 |
| US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
| EP3372242A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| EP3372241A1 (en) * | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
| KR102867311B1 (ko) * | 2017-08-11 | 2025-10-01 | 리서치 디벨럽먼트 파운데이션 | 증강된 혈청 반감기를 위한 조작된 항체 fc 변이체 |
| KR20190024572A (ko) * | 2017-08-30 | 2019-03-08 | (주)셀트리온 | TNFα 관련 질환을 치료하기 위한 피하 투여 요법 |
| TW202423960A (zh) | 2017-09-29 | 2024-06-16 | 日商中外製藥股份有限公司 | 具有第viii凝血因子(fviii)輔因子機能替代活性的多重特異性抗原結合分子及含有此分子作為有效成分之藥學製劑 |
| BR112020008393A2 (pt) | 2017-11-01 | 2020-11-03 | Chugai Seiyaku Kabushiki Kaisha | variante e isoforma de anticorpos com atividade biológica reduzida |
| IL276286B2 (en) * | 2018-01-26 | 2025-07-01 | Genzyme Corp | FC variants with improved binding to FCRN and extended half-life |
| US12565664B2 (en) * | 2019-03-05 | 2026-03-03 | The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) | Genome-edited birds |
| CN115770291A (zh) * | 2021-09-08 | 2023-03-10 | 珠海市丽珠单抗生物技术有限公司 | 新型冠状病毒SARS-CoV-2疫苗加强免疫及其应用 |
| CN115770292A (zh) * | 2021-09-08 | 2023-03-10 | 珠海市丽珠单抗生物技术有限公司 | 新型冠状病毒SARS-CoV-2的协同免疫及其用途 |
| TW202330032A (zh) * | 2021-11-30 | 2023-08-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 一種抗sost抗體醫藥組成物及其用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US6090382A (en) | 1996-02-09 | 2000-07-18 | Basf Aktiengesellschaft | Human antibodies that bind human TNFα |
| DE122004000004I1 (de) * | 1996-02-09 | 2004-08-12 | Abott Biotechnology Ltd | Humane Antikörper welche an Humanen TNFalpha binden. |
| AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| KR101077001B1 (ko) | 1999-01-15 | 2011-10-26 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| PT1355919E (pt) * | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US7658921B2 (en) * | 2000-12-12 | 2010-02-09 | Medimmune, Llc | Molecules with extended half-lives, compositions and uses thereof |
| US20040033228A1 (en) * | 2002-08-16 | 2004-02-19 | Hans-Juergen Krause | Formulation of human antibodies for treating TNF-alpha associated disorders |
| DK1562972T3 (da) | 2002-10-15 | 2010-12-06 | Facet Biotech Corp | Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| US8163881B2 (en) | 2005-05-31 | 2012-04-24 | The Board Of Regents Of The University Of Texas System | Immunoglobulin molecules with improved characteristics |
| NZ576133A (en) * | 2006-10-27 | 2012-10-26 | Abbott Biotech Ltd | Crystalline anti-htnfalpha antibodies |
| WO2009024567A1 (en) | 2007-08-20 | 2009-02-26 | Glaxo Group Limited | Production method |
| EP2641919A3 (en) * | 2007-11-30 | 2014-05-07 | Glaxo Group Limited | Antigen-binding constructs |
| NZ622583A (en) * | 2007-11-30 | 2015-08-28 | Abbvie Biotechnology Ltd | Protein formulations and methods of making same |
| WO2009073805A2 (en) * | 2007-12-04 | 2009-06-11 | Verdezyne, Inc. | Aglycosylated therapeutic antibodies and therapeutic antibody-encoding nucleotide sequences |
| PL2808343T3 (pl) * | 2007-12-26 | 2019-11-29 | Xencor Inc | Warianty Fc ze zmienionym wiązaniem do FcRn |
| EP2225276B1 (en) * | 2007-12-31 | 2014-04-23 | Bayer Intellectual Property GmbH | Antibodies to tnf alpha |
| FR2934599B1 (fr) | 2008-07-29 | 2012-12-21 | Arkema France | Fabrication de polyethylene a partir de matieres renouvelables, polyethylene obtenu et utilisations |
| EP2362767B1 (en) * | 2008-10-29 | 2017-12-06 | Ablynx N.V. | Formulations of single domain antigen binding molecules |
| CA2753287A1 (en) * | 2009-02-24 | 2010-09-02 | Glaxo Group Limited | Antigen-binding constructs |
| SG173705A1 (en) * | 2009-03-05 | 2011-09-29 | Abbott Lab | Il-17 binding proteins |
| RU2560701C2 (ru) | 2009-05-04 | 2015-08-20 | Эббви Байотекнолоджи Лтд. | Стабильные композиции с высокими концентрациями белков антител человека против tnf-альфа |
| US20120076787A1 (en) * | 2009-05-28 | 2012-03-29 | Peter Adamson | Combination of a tnf-alpha antagonist and a vegf antagonist for use in the treatment or prevention of diseases of the eye |
| WO2011074965A1 (en) * | 2009-12-17 | 2011-06-23 | Stichting Sanquin Bloedvoorziening | Methods and means for counteracting an activity of an fc domain |
| AU2011325974B2 (en) | 2010-11-11 | 2016-10-27 | Abbvie Biotechnology Ltd. | Improved high concentration anti-TNFalpha antibody liquid formulations |
-
2011
- 2011-07-19 GB GBGB1112429.4A patent/GB201112429D0/en not_active Ceased
-
2012
- 2012-07-19 EP EP15197750.1A patent/EP3009450A1/en not_active Withdrawn
- 2012-07-19 CN CN201280034887.5A patent/CN103748110A/zh active Pending
- 2012-07-19 PH PH1/2014/500167A patent/PH12014500167A1/en unknown
- 2012-07-19 CA CA2841105A patent/CA2841105A1/en not_active Abandoned
- 2012-07-19 AU AU2012285786A patent/AU2012285786B2/en not_active Ceased
- 2012-07-19 EP EP12738101.0A patent/EP2734548B1/en active Active
- 2012-07-19 EA EA201391789A patent/EA201391789A1/ru unknown
- 2012-07-19 MX MX2014000739A patent/MX2014000739A/es unknown
- 2012-07-19 BR BR112014000341A patent/BR112014000341A2/pt not_active IP Right Cessation
- 2012-07-19 JP JP2014520658A patent/JP2014524748A/ja active Pending
- 2012-07-19 US US13/988,400 patent/US20130243764A1/en not_active Abandoned
- 2012-07-19 SG SG10201601154QA patent/SG10201601154QA/en unknown
- 2012-07-19 KR KR1020147004161A patent/KR20140054085A/ko not_active Withdrawn
- 2012-07-19 ES ES12738101.0T patent/ES2600854T3/es active Active
- 2012-07-19 PE PE2014000086A patent/PE20141660A1/es not_active Application Discontinuation
- 2012-07-19 WO PCT/EP2012/064129 patent/WO2013011076A2/en not_active Ceased
-
2014
- 2014-01-06 ZA ZA2014/00062A patent/ZA201400062B/en unknown
- 2014-01-17 CL CL2014000134A patent/CL2014000134A1/es unknown
- 2014-01-17 DO DO2014000007A patent/DOP2014000007A/es unknown
- 2014-01-20 CR CR20140029A patent/CR20140029A/es unknown
- 2014-01-21 CO CO14011137A patent/CO6862106A2/es not_active Application Discontinuation
- 2014-02-12 MA MA36748A patent/MA35345B1/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014524748A5 (enExample) | ||
| JP6746564B2 (ja) | Il−23a及びtnf−アルファを標的とする化合物ならびにその使用 | |
| RU2015130100A (ru) | TNF-альфа антиген-связывающие белки | |
| JP2015522252A5 (enExample) | ||
| JP2013544492A5 (enExample) | ||
| CN115397852B (zh) | 工程化抗il-2抗体 | |
| RU2016129113A (ru) | Антитела к pd-1 собак | |
| JP2018521691A5 (enExample) | ||
| JP2018502060A5 (enExample) | ||
| JP2014508511A5 (enExample) | ||
| CA2792740A1 (en) | Antibodies with ph dependent antigen binding | |
| RU2011101969A (ru) | Антитела к человеческому интерлейкину-20 | |
| JP7689116B2 (ja) | Pd1およびvegfr2二重結合剤 | |
| JPWO2019023564A5 (enExample) | ||
| CA3213751A1 (en) | Fusion proteins, pharmaceutical compositions, and therapeutic applications | |
| TW202243689A (zh) | 抗cd20/抗cd3雙特異性抗體及抗cd78b抗體藥物結合物的組合治療之給藥 | |
| KR20230044448A (ko) | 항-pd-1 항체 약학적 조성물 및 이의 용도 | |
| RU2015129655A (ru) | Антитело человека, специфичное к матапневмовирусу человека, или антиген-связывающий фрагмент указанного антитела | |
| KR20250067124A (ko) | 이중특이성 항-c-kit 및 항-cd203c 항원 결합 분자 및 이의 용도 | |
| US20240327483A1 (en) | Fusion proteins comprising suppression of tumorigenicity 2 or interleukin-33, pharmaceutical compositions, and therapeutic applications | |
| TW202124432A (zh) | 使用pd-1軸抑制劑及抗骨膜蛋白抗體治療癌症之方法 | |
| EP4190352B1 (en) | Formulation of novel bispecific anti-cd3/cd20 polypeptide complex | |
| CA3227386A1 (en) | Interleukin-2 muteins, fusion proteins, pharmaceutical compositions, and therapeutic applications | |
| CA3091307A1 (en) | Csf1r binding agents | |
| JP2022513671A (ja) | Cd40抗体医薬品組成物およびその使用 |